Antibiotic impregnated catheters are antimicrobial catheter that have been introduced with the primary objective of reducing the incidence of shunt related infections.

The incidence of shunt infection is still high despite routine administration of perioperative antibiotics. A lower incidence of shunt infection was observed when antibiotic impregnated shunts (AIS) were used to treat hydrocephalus and a rapid cure was reported in cases of ventriculitis when antibiotics were injected into external ventricular drain (EVD).

Designed to reduce the colonization of gram positive bacteria. Laboratory tests show these antibiotic-impregnated catheters provide antimicrobial activity for at least the first 31 days, the time when patients are most susceptible to shunt infections 1) 2) 3) 4)

AIC catheters slowly release antibiotics over several weeks to prevent the colonization of shunt systems by gram-positive bacteria, which account for most shunt infections 5) 6) 7) 8) 9) 10).

The bulk of the literature to date has demonstrated a reduction in shunt-associated infections associated with the use of AICs; however, there has been some reluctance to adopt these systems because of their increased cost compared with conventional catheters 11) 12) 13) 14) 15) 16).

AI catheters were found to be associated with a significant reduction in infection incidence, resulting in tremendous cost savings. AI catheters were associated with a cost savings of $42,125 and $230,390 per 100 de novo shunts placed in adult and pediatric patients, respectively 17).

Antibiotic-impregnated shunts have yet to find widespread use in the developing world, largely due to cost. Given potential differences in the microbial spectrum, their effectiveness in preventing shunt infection for populations in low-income countries may differ and has not been demonstrated 18)

Bactiseal C and NC


Ares Antibiotic Impregnated Catheter

A study determined the protective effect of antibacterial processing of cerebrospinal fluid (CSF) shunt catheters against infection with staphylococci, which is an important complication following CSF shunt placement for hydrocephalus. Also examined is the effect of a conditioning film such as that seen on the luminal surface of shunts used in posthemorrhagic hydrocephalus. Conventional preventative measures, including antimicrobial prophylaxis, confer a temporary or unproven benefit. Bayston et al. have therefore developed a process for impregnation of CSF shunts with rifampicin and clindamycin, and this has been shown previously to achieve the target duration of 28 days of protective activity in vitro. The present study demonstrates the limit of the period of protection and the efficacy of the processing against a wide range of staphylococci, particularly in the presence of a plasma protein conditioning film. Five strains of Staphylococcus aureus and 17 coagulase-negative staphylococci, all clinical isolates, were inoculated into the shunts at 2-week intervals until failure of antimicrobial protection occurred. The results showed that the process protected against all strains for between 42 and 56 days and that the conditioning film did not diminish the protection 19).

Concern has arisen over the effect of released antimicrobial agents from antibiotic-impregnated external ventricular drainage (EVD) catheters on the reliability of CSF culture for diagnosis of ventriculitis.

Bayston et al. designed a laboratory study to investigate this possibility, and to determine whether there was also a risk of loss of bacterial viability when CSF samples were delayed in transport to the laboratory. METHODS Three types of commercially available antibiotic-impregnated EVD catheters were perfused with a suspension of bacteria (Staphylococcus epidermidis) over 21 days. Samples were analyzed for bacterial viability and for concentrations of antibiotics released from the catheters. The authors also investigated the effect on bacterial viability in samples stored at 18°C and 4°C to simulate delay in CSF samples reaching the laboratory for analysis. RESULTS Bacterial viability was significantly reduced in all 3 catheter types when sampled on Day 1, but this effect was not observed in later samples. The results were reflected in stored samples, with significant loss of viability in Day 1 samples but with little further loss of viable bacteria in samples obtained after this time point. All samples stored for 18 hours showed significant loss of viable bacteria. CONCLUSIONS While there were differences between the catheters, only samples taken on Day 1 showed a significant reduction in the numbers of viable bacteria after passing through the catheters. This reduction coincided with higher concentrations of antimicrobial agents in the first few hours after perfusion began. Similarly, bacterial viability declined significantly after storage of Day 1 samples, but only slightly in samples obtained thereafter. The results indicate that drugs released from these antimicrobial catheters are unlikely to affect the diagnosis of ventriculitis, as sampling for this purpose is not usually conducted in the first 24 hours of EVD 20).


The majority of data derive from studies on the effectiveness of AICs, followed by studies on the effectiveness of silver impregnated catheter SCCs. Statistical heterogeneity was observed in several analyses. Antimicrobial shunt catheters (AICs, SCCs) were associated with lower risk for CSF catheter-associated infections than conventional catheters (CCs) (RR 0.44, 95% CI 0.35-0.56). Fewer infections developed in the patients treated with antimicrobial catheters regardless of randomization, number of participating centers, funding, shunting or ventricular drainage, definition of infections, de novo implantation, and rate of infections in the study. There was no difference regarding gram-positive bacteria, all staphylococci, coagulase-negative streptococci, and Staphylococcus aureus, when analyzed separately. On the contrary, the risk for methicillin-resistant S. aureus (MRSA, RR 2.64, 95% CI 1.26-5.51), nonstaphylococcal (RR 1.75, 95% CI 1.22-2.52), and gram-negative bacterial (RR 2.13, 95% CI 1.33-3.43) infections increased with antimicrobial shunt catheters.

Based on data mainly from nonrandomized studies, AICs and SCCs reduce the risk for infection in patients undergoing CSF shunting. Future studies should evaluate the higher risk for MRSA and gram-negative infections. Additional trials are needed to investigate the comparative effectiveness of the different types of antimicrobial catheters 21).

Cui et al. evaluated the efficacy of antibiotic impregnated catheter (AIC) and silver impregnated catheter compared with plain catheters for the prevention of catheter related infections (CRI).

The authors performed an independent search of Medline, Embase, and the Cochrane Library to identify eligible studies published between January 2002 and August 2014.

They searched all relevant literature using an exhaustive search strategy. Randomized controlled trials or observational studies that compared (AIC) catheters with plain catheters for the prevention of CRI were included. The quality of each included study was assessed using a risk of bias assessment tool and the Newcastle-Ottawa Scale. RevMan5.3 software (The Cochrane Collaboration, Oxford, UK) was used to perform this meta-analysis, and publication bias was investigated using funnel plot constructions and Egger test.

A total of 4 randomized and 10 observational studies involving 4,399 patients were included in this metaanalysis. Pooled results comparing AIC catheters with plain EVD catheters in the management of patients with acute high intracranial pressure demonstrated the superiority of antimicrobial EVDs for the prevention of CRI with a risk induction of 62% (95% confidence interval [CI], 0.25-0.58; P < .00001). Subgroup analyses of pooled data from separate analyses of AIC and SIC showed the efficacy of both measures for CRI prevention, with a risk ratio (RR) of 0.31 (95% CI, 0.18-0.55; P < .0001) and an RR of 0.59 (95% CI, 0.40-0.88; P = .010), respectively. The protective effects of these AIC catheters remained significant in the subgroup of randomized controlled trials with an RR of 0.48 (95% CI, 0.25-0.90; P = .02). A similar result was also seen after a pooled analysis of observational studies with an RR of 0.35 (95% CI, 0.21-0.60; P = .0001). The heterogeneity among studies was moderate (I(2) = 49%) and was primarily attributed to the inclusion of 1 large, positive cohort study. Publication bias was unlikely in the current meta-analysis.

The restults indicate that both AIC and SIC are more effective than plain EVDs for the prevention of CRI. There is no conclusive evidence on the preference of AIC vs SIC because of insufficient data. Further well-designed, multicenter randomized controlled trials are required to confirm the findings of this meta-analysis 22).

The current value analysis demonstrates that evidence supports the use of AICs as effective and potentially cost-saving treatment 23).

see Antibiotic impregnated shunt

Antibiotic impregnated catheter case series.

Bayston R, Ashraf W, Bhundia C. Mode of action of an antimicrobial biomaterial for use in hydrocephalus shunts. Journal of Antimicrobial Chemotherapy 2004; 53:778-782.
Pattavilakom A, Kotasnas D, Korman TM, Xenos C, Danks A. Duration of in vivo antimicrobial activity of antibiotic-impregnated cerebrospinal fluid catheters. Neurosurgery 2006; 58:930-935.
Richards HK, Seeley HM, Pickard JD. Efficacy of antibiotic-impregnated shunt catheters in reducing shunt infection: data from the United Kingdom Shunt Registry. J Neurosurg Pediatrics 2009; 4:389-393.
Parker SL, Attenello FJ, Sciubba DM, Garces-Ambrossi GL, Ahn E, Weingart J, Carson B, Jallo GI. Comparison of shunt infection incidence in high-risk subgroups receiving antibiotic-impregnated versus standard shunts. Childs Nerv Syst 2009; 25:77-83.
L.F. Borges Cerebrospinal fluid shunts interfere with host defenses Neurosurgery, 10 (1982), pp. 55–60
S.H. Farber, S.L. Parker, O. Adogwa, M.J. McGirt, D. Rigamonti Effect of antibiotic-impregnated shunts on infection rate in adult hydrocephalus: a single institution's experience Neurosurgery, 69 (2011), pp. 625–629 [discussion 629]
M.J. McGirt, A. Zaas, H.E. Fuchs, T.M. George, K. Kaye, D.J. Sexton Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens Clin Infect Dis, 36 (2003), pp. 858–862
S.L. Parker, W.N. Anderson, S. Lilienfeld, J.T. Megerian, M.J. McGirt Cerebrospinal shunt infection in patients receiving antibiotic-impregnated versus standard shunts J Neurosurg Pediatr, 8 (2011), pp. 259–265
.K. Pople, R. Bayston, R.D. Hayward Infection of cerebrospinal fluid shunts in infants: a study of etiological factors J Neurosurg, 77 (1992), pp. 29–36
D.M. Sciubba, J.C. Noggle, B.S. Carson, G.I. Jallo Antibiotic-impregnated shunt catheters for the treatment of infantile hydrocephalus Pediatr Neurosurg, 44 (2008), pp. 91–96
M. Choux, L. Genitori, D. Lang, G. Lena Shunt implantation: reducing the incidence of shunt infection J Neurosurg, 77 (1992), pp. 875–880
R. Eymann, S. Chehab, M. Strowitzki, W.I. Steudel, M. Kiefer Clinical and economic consequences of antibiotic-impregnated cerebrospinal fluid shunt catheters J Neurosurg Pediatr, 1 (2008), pp. 444–450
P. Gardner, T. Leipzig, P. Phillips Infections of central nervous system shunts Med Clin North Am, 69 (1985), pp. 297–314
J.R. Kestle, H.J. Hoffman, D. Soloniuk, R.P. Humphreys, J.M. Drake, E.B. Hendrick A concerted effort to prevent shunt infection Childs Nerv Syst, 9 (1993), pp. 163–165
A. Pattavilakom, C. Xenos, O. Bradfield, R.A. Danks Reduction in shunt infection using antibiotic impregnated CSF shunt catheters: an Australian prospective study J Clin Neurosci, 14 (2007), pp. 526–531
R. Ritz, F. Roser, M. Morgalla, K. Dietz, M. Tatagiba, B.E. Will Do antibiotic-impregnated shunts in hydrocephalus therapy reduce the risk of infection? An observational study in 258 patients BMC Infect Dis, 7 (2007), p. 38
Parker SL, McGirt MJ, Murphy JA, Megerian JT, Stout M, Engelhart L. Cost savings associated with antibiotic-impregnated shunt catheters in the treatment of adult and pediatric hydrocephalus. World Neurosurg. 2015 Mar;83(3):382-6. doi: 10.1016/j.wneu.2014.06.010. Epub 2014 Jun 13. PubMed PMID: 24933241.
Lane JD, Mugamba J, Ssenyonga P, Warf BC. Effectiveness of the Bactiseal Universal Shunt for reducing shunt infection in a sub-Saharan African context: a retrospective cohort study in 160 Ugandan children. J Neurosurg Pediatr. 2014 Feb;13(2):140-4. doi: 10.3171/2013.11.PEDS13394. Epub 2013 Dec 6. PubMed PMID: 24313655.
Bayston R, Lambert E. Duration of protective activity of cerebrospinal fluid shunt catheters impregnated with antimicrobial agents to prevent bacterial catheter-related infection. J Neurosurg. 1997 Aug;87(2):247-51. PubMed PMID: 9254088.
Bayston R, Ashraf W, Ortori C. Does release of antimicrobial agents from impregnated external ventricular drainage catheters affect the diagnosis of ventriculitis? J Neurosurg. 2015 Jun 12:1-7. [Epub ahead of print] PubMed PMID: 26067618.
Konstantelias AA, Vardakas KZ, Polyzos KA, Tansarli GS, Falagas ME. Antimicrobial-impregnated and -coated shunt catheters for prevention of infections in patients with hydrocephalus: a systematic review and meta-analysis. J Neurosurg. 2015 May;122(5):1096-112. doi: 10.3171/2014.12.JNS14908. Epub 2015 Mar 13. Review. PubMed PMID: 25768831.
Cui Z, Wang B, Zhong Z, Sun Y, Sun Q, Yang G, Bian L. Impact of antibiotic- and silver-impregnated external ventricular drains on the risk of infections: A systematic review and meta-analysis. Am J Infect Control. 2015 Jul 1;43(7):e23-32. doi: 10.1016/j.ajic.2015.03.015. Epub 2015 Apr 29. PubMed PMID: 25934064.
Edwards NC, Engelhart L, Casamento EM, McGirt MJ. Cost-consequence analysis of antibiotic-impregnated shunts and external ventricular drains in hydrocephalus. J Neurosurg. 2015 Jan;122(1):139-47. doi: 10.3171/2014.9.JNS131277. Review. PubMed PMID: 25380105.
  • antibiotic_impregnated_catheter.txt
  • Last modified: 2021/04/28 10:41
  • by administrador